BA
ABMD

BKS Advisors’s Abiomed Inc ABMD Stock Holding History

BKS Advisors’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-15,955
Closed -$6.53M – 244
2018
Q2 		$6.53M Sell
15,955
-1,050
-6% -$380K 2.31% 5
2018
Q1 		$4.95M Sell
17,005
-1,400
-8% -$355K 1.81% 13
2017
Q4 		$3.45M Sell
18,405
-675
-4% -$126K 1.25% 22
2017
Q3 		$3.22M Hold
19,080
– – 1.25% 23
2017
Q2 		$2.73M Buy
19,080
+3,590
+23% +$482K 1.11% 26
2017
Q1 		$1.94M Sell
15,490
-3,810
-20% -$442K 0.85% 36
2016
Q4 		$2.17M Hold
19,300
– – 1.02% 33
2016
Q3 		$2.48M Buy
+19,300
New +$2.31M 1.14% 26

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

BKS Advisors's ABMD Position: Q3 2018 in Review

BKS Advisors sold out of Abiomed Inc (ABMD) in Q3 2018, closing a stake of 15,955 shares — an estimated $6.53M sold.

BKS Advisors first reported a position in ABMD in Q3 2016 and held it in 8 quarters. The position peaked at $6.53M in Q2 2018. 529 funds tracked by Wall St. Rank hold ABMD as of Q3 2018.

  • BKS Advisors reported no remaining Abiomed Inc position as of Q3 2018 after selling out during the quarter.
  • BKS Advisors sold 15,955 Abiomed Inc shares in Q3 2018, an estimated $6.53M.
  • BKS Advisors first reported a position in Abiomed Inc in Q3 2016 and held it in 8 quarters.
  • BKS Advisors's Abiomed Inc position peaked at $6.53M in Q2 2018.
  • 529 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2018.

Based on BKS Advisors's 13F filing for Q3 2018, filed 26 Oct 2018.